{"id":372,"date":"2014-10-23T12:00:23","date_gmt":"2014-10-23T16:00:23","guid":{"rendered":"http:\/\/www.gqr-lmc-nmp.ca\/?page_id=372"},"modified":"2017-02-08T13:10:32","modified_gmt":"2017-02-08T18:10:32","slug":"mpn-registry","status":"publish","type":"page","link":"https:\/\/www.gqr-lmc-nmp.ca\/system\/myeloproliferative-neoplasms-mpn\/mpn-registry\/?lang=en","title":{"rendered":"MPN Registry"},"content":{"rendered":"

Patient with MPN (essential thrombocytosis (ET), polycythemia vera (PV) and myelofibrosis (MF) have received far less therapeutic progress than those with CML over the last decade. Collecting data on treatment choices, response therapies and side effects would help to caracterize unmet medical needs in the population of patients with MPN and to help optimize care and treatment of these patient. The purpose of the MPN registry is to identify and caracterize the not satisfied medical needs of the population by :<\/p>\n

    \n
  1. Providing epidemiological and descriptive data on current trends in diagnosis and therapeutic intervention;<\/li>\n
  2. Describing the impact of treatment on the quality of life of patients;<\/li>\n
  3. Describing the adverse effects of treatments and the effectiveness of their management.<\/li>\n<\/ol>\n

    In addition, this registry provides a list of participants who have agreed to be recontacted for future studies approved by their institution’s Research Ethics Board (REB), to assess medical practice and to identify the need for Professional development among physicians.<\/p>\n

     <\/p>\n

    Recruitment for the LMC-NMP GQR NMP Registry began on March 5, 2015. To date, 7 sites have been activated and more than 400 participants have been recruited.<\/span><\/p>\n

     <\/p>\n

    Participating sites and local principal investigator<\/strong><\/h2>\n

     <\/p>\n

      \n
    • H\u00f4pital Maisonneuve-Rosemont \u2013 Dr Lambert Busque<\/li>\n
    • H\u00f4pital g\u00e9n\u00e9ral Juif \u2013 Dre Shireen Sirhan<\/li>\n
    • CHU de Qu\u00e9bec \u2013 Dr Robert Delage<\/li>\n
    • H\u00f4pital du Sacr\u00e9-C\u0153ur de Montr\u00e9al \u2013 Dre In\u00e8s Chamaki<\/li>\n
    • Cit\u00e9 de la Sant\u00e9 de Laval \u2013 Dre Danielle Talbot<\/li>\n
    • H\u00f4tel-Dieu de L\u00e9vis \u2013 Dr Marc Lalancette<\/li>\n
    • H\u00f4pital Charles-LeMoyne \u2013 Dr Pierre Desjardins<\/li>\n
    • H\u00f4pital Ste-Mary \u2013 Dr Jaroslav Prchal (coming soon)<\/li>\n
    • Centre hospitalier universitaire de Sherbrooke \u2013 Dr Michel Pavic (coming soon)<\/li>\n<\/ul>\n

       <\/span><\/span><\/p>\n

       <\/p>\n","protected":false},"excerpt":{"rendered":"

      Patient with MPN (essential thrombocytosis (ET), polycythemia vera (PV) and myelofibrosis (MF) have received far less therapeutic progress than those\u2026<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":368,"menu_order":20,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/pages\/372"}],"collection":[{"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/comments?post=372"}],"version-history":[{"count":5,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/pages\/372\/revisions"}],"predecessor-version":[{"id":723,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/pages\/372\/revisions\/723"}],"up":[{"embeddable":true,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/pages\/368"}],"wp:attachment":[{"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/media?parent=372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}